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A NOVEL METHOD FOR ESTIMATING THE EFFECTS OF ADHERENCE 
TO ANTIHYPERTENSIVES AND DURATION OF DRUG ACTION ON 
CARDIOVASCULAR RISK
Lowy A, Brede Y
Novartis Pharma AG, Basel, Switzerland
Most patients miss occasional doses of antihypertensive treatment. The consequent 
loss of blood pressure (BP) control, and thus increased cardiovascular risk, may be 
mitigated by prescribing “forgiving” drugs that have a duration of antihypertensive 
effect beyond the 24-hour dosing interval. However, the consequences of missed doses 
for cardiovascular outcomes, and additional impact of duration of drug action, have 
not been evaluated quantitatively. We developed a method to quantify the chain of 
factors linking adherence and duration of drug action with outcomes; an important 
consideration given that adherence and hence BP reduction in real-world clinical 
practice are typically much lower than in randomised controlled trials. The method 
involves simulating 256-day dosing histories for 1250 individuals, incorporating real-
istically distributed gaps in dosing based on a study of electronically monitored dosing 
records from 4783 hypertensive patients in clinical trials. Percentage adherence is 
adjusted by altering the proportion of doses missed while preserving a realistic distri-
bution of gap length. Systolic BP (SBP) reduction for each patient is estimated, with 
rises and falls according to the individual’s dosing behaviour. By averaging SBP reduc-
tions over time and individuals, population mean SBP reduction is estimated. Cardio-
vascular disease (CVD) risk over, for example, 10 years may then be predicted using 
the Framingham Risk Equation, with baseline characteristics from NHANES 2005–
2006 (average data: age 65.2 years; 52.9% women; SBP 155.95 mmHg; total choles-
terol 5.41 mmol/L) and baseline absolute 10-year CVD risk of 27.0%. The method 
allows variable inputs including adherence level (%), rate of loss of antihypertensive 
effect when treatment is interrupted (mmHg/day), rate of BP reduction when treatment 
is (re)started (mmHg/day) and SBP-lowering effect of uninterrupted treatment 
(mmHg). In conclusion, we describe a novel method that allows quantiﬁ cation of the 
effects of treatment adherence and antihypertensive drug forgiveness on clinical out-
comes (i.e. SBP and CVD risk reduction).
PCV142
AN APPLICATION OF IMPUTATION TECHNIQUES TO IMPROVE DATA 
AVAILABILITY FROM ELECTRONIC MEDICAL RECORDS
Exuzides A, Colby C
ICON Clinical Research, San Francisco, CA, USA
OBJECTIVES: Analytic data sets based on electronic Medical Records (eMRs) offer 
long and detailed patient follow-up, large sample sizes, and a rich set of variables. 
However, the existence of a particular variable within an eMR is no assurance of 
actual data availability for all patients. Patients may receive lab tests irregularly or 
miss visits. Reporting standards can vary within an eMR system, creating large 
numbers of patients with missing data. We present details from a three step imputation 
process to improve eMR data availability from an observational study of hypertension 
outcomes. METHODS: We used an analytic data set comprised of 227,257 patients 
from 10 participating medical centers. One important element of the study was the 
computation of a cardiovascular risk score based on 11 demographic and clinical 
variables available from eMRs. However, only 43,676 patients (19%) had complete 
data for all 11 variables. To increase the sample size of patients with complete data 
for all 11 variables, we used three imputation techniques: we ﬁ rst allowed for lab and 
blood pressure values to be carried forward to replace missing values; we then aug-
mented a missing diabetes status with pharmacy data by using diabetes-speciﬁ c medi-
cations to indicate a positive diabetes history; and, ﬁ nally, we applied a multiple 
imputation (MI) technique, based on a Markov Chain Monte Carlo (MCMC) 
approach, implemented using SAS® PROC MI. RESULTS: After application of the 
three data imputation techniques, the sample size of patients with complete or imputed 
data for all 11 variables increased to 75,209 (33%). This amounts to a substantial 
increase (72%) in the number of patients with all critical variables available to be used 
for further analysis. CONCLUSIONS: Proper application of imputation techniques, 
including MI, can yield a substantial increase in the number of patients available for 
analysis. 
GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
PGI1
A SYSTEMATIC REVIEW OF THE DIAGNOSTIC ACCURACY OF 
SEROLOGIC TESTS IN THE DIAGNOSIS OF CELIAC DISEASE
Costa V1, Chandra KM2, McCurdy B1, Ieraci L3, Levin L1
1Ontario Ministry of Health and Long-term Care, Toronto, ON, Canada; 2McMaster 
University, Hamilton, ON, Canada; 3Toronto Health Economics and Technology Assessment 
(THETA) Collaborative, Toronto, ON, Canada
OBJECTIVES: To evaluate the diagnostic accuracy of IgA (immunoglobulin A) and 
IgG serologic tests in the diagnosis of celiac disease including anti-tissue transgluta-
minase (tTG) antibody, anti-deamidated gliadin peptide antibody (DGP), anti-endo-
mysial antibody (EMA), and anti-gliadin antibodies (AGA). METHODS: A systematic 
review of the peer-reviewed literature was conducted to identify studies that evaluated 
the sensitivity and speciﬁ city of serologic celiac disease tests using small bowel biopsy 
as the gold standard. The patient population consisted of untreated, undiagnosed 
subjects with symptoms consistent with the disease. Pooled estimates of sensitivity and 
speciﬁ city were calculated using a bivariate, binomial generalized linear mixed model 
(SAS 9.2) which takes into account the negative correlation between sensitivity and 
speciﬁ city. Statistical signiﬁ cance was deﬁ ned by p-values less than 0.05, where “false 
discovery rate” adjustments were made for multiple hypothesis testing. RESULTS: In 
total, 17 studies were eligible for the analysis. The pooled analysis showed that IgA 
tTG has a sensitivity of 92.1% (95% CI 88.0, 96.3), compared to 89.2% (83.3, 95.1, 
p = 0.12) for IgA DGP, 85.1% (79.5, 94.4, p = 0.07) for IgA EMA, 74.9% (63.6, 
86.2, p = 0.0003) for IgA AGA. Combining more than one serologic test slightly 
increased the sensitivity, 95.1% (92.2, 98%, p = 0.039 vs. IgA tTG). The pooled 
sensitivity of IgG DGP was 88.4% (95% CI: 82.1, 94.6), 44.7% (30.3, 59.2, p = 
0.0003) for IgG tTG, and 69.1% (56.0, 82.2, p = 0.34) for IgG AGA. Speciﬁ city 
ranged from 90.1% to 93.9% and was similar among the different tests. The quality 
of the evidence according to the GRADE Working Group criteria was considered 
“moderate” for IgA tTG and EMA, “low” for IgA DGP and test combinations, and 
“very low” for IgA AGA. CONCLUSIONS: The evidence available suggests that IgA 
tTG has a higher accuracy than other serologic tests. Combining more than one 
serologic test contributes little to the diagnostic accuracy.
PGI2
IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY 
WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE 
PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH 
TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS 
C VIRUS (HCV) INFECTION PATIENTS
Barros FMR1, Cheinquer H2, Borges LG3, Santos E3
1Hospital Português de Beneﬁ cência em Pernambuco and Hospital das Clínicas—UFPE, 
Recife, Brazil; 2Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto 
Alegre, Brazil; 3Roche Brazil, São Paulo, Brazil
OBJECTIVES: Until recently, few head-to-head trials evaluated the efﬁ cacy of pegin-
terferon-alpha-2a versus peginterferon-alpha-2b and none meta-analysis was available 
so far. In 2010, a meta-analysis performed by Awad et al was able to demonstrate 
that peginterferon-alpha-2a was more efﬁ cacious in achieving sustained virological 
response as compared to peginterferon-alpha-2b. McHutchison 2009, one of the 
studies included in the meta-analysis, evaluated two different doses of peginterferon-
alpha-2b (standard-dose: 1,5 mcg/kg; low-dose: 1,0 mcg/kg), raising doubts about 
possible negative impact of lower dose on the analysis results.We aim to compare 
treatment outcomes in genotypes 1/4 HCV infection treated with peginterferon-alpha-
2a versus peginterferon-alpha-2b at standard-dose (per package insert) both plus riba-
virin in order to assess efﬁ cacy, performing a systematic review and meta-analysis of 
published randomized controlled trials (RCTs). METHODS: An extensive search 
through main medical information databases (MEDLINE, Cochrane Library, Embase 
and Lilacs) and specialized websites was conducted on the second trimester of 2010. 
We aim to indentify RCTs which evaluate treatment efﬁ cacy of peginterferon-alpha-2a 
versus standard-dose peginterferon-alpha-2b both plus ribavirin for HCV treatment 
in genotypes 1/4 patients not co-infected with HIV. According to heterogeneity test, 
a ﬁ xed or a random-effect model was adopted. RESULTS: Only 6 papers out of 623 
found (databases citation without duplicates plus manual searches) met our inclusion 
criteria: 1)Ascione, 2009; 2)Rumi, 2009; 3)McHutchison, 2009; 4)Yenice, 2006; 5)
Scotto, 2008; 6)Berak, 2007. For genotypes 1/4 chronic HCV infection patients, 
peginterferon-alpha-2a showed higher SVR as compared to standard dose of pegin-
terferon-alpha-2b: 42.09% versus 33.44% (RR = 1.10, IC 95% 1.006–1.202, assum-
ing a ﬁ xed-effect framework). CONCLUSIONS: According to these results, no 
signiﬁ cant impact on already published meta-analysis results was observed when lower 
dose peginterferon-alpha-2b patients were excluded from the analysis. In summary, 
peginterferon-alpha-2a is more effective in treating genotypes 1/4 HCV infected 
patients as compared to standard-dose peginterferon-alpha-2b, both in association 
with ribavirin.
PGI3
EFFICACY OF ANTIBIOTICS AND PROBIOTICS IN MANAGEMENT OF 
POUCHITIS; A META-ANALYSIS
Abdollahi M1, Nikfar S2, Darvish Damavandi M3
1Faculty of Pharmacy; and Pharmaceutical Sciences Research Center, Tehran University of 
Medical Sciences, Tehran, Iran; 2Tehran University of Medical Sciences, Faculty of Pharmacy 
and Food & Drug Laboratory Research Center, Iran MOH, Tehran, Iran; 3Faculty of Science, 
National University of Singapore, Singapore
OBJECTIVES: Pouchitis is the most frequent long-term complication of ileal pouch-
anal anastomosies (IPAA) surgery for ulcerative colitis (UC) which is a nonspeciﬁ c 
inﬂ ammation of the ileal reservoir. Its clinical frequency varies depending on the deﬁ ni-
tion and the follow up but is approximately 50% after a decade. Antibiotics and 
probiotics are currently the most widely accepted treatment in pouchitis patients. 
Objective of this study was to meta-analyze efﬁ cacy of probiotics and antibiotics in 
the management of pouchitis. METHODS: All databases specially Pubmed, Web of 
Science, Scopus, Cochrane, and Google Scholar were searched between 1965 and 
December 2009, and relevant controlled clinical trials were extracted, reviewed, and 
validated according to the study protocol. The outcome of interest was deﬁ ned by a 
pouchitis disease activity index (PDAI) < 7. Thirteen clinical trials were included in 
the meta-analysis. RESULTS: Pooling of the results from eight trials yielded a relative 
risk (RR) of 5.33 with a 95% CI of 2.12–13.35 and a signiﬁ cant RR (P = 0.0004) in 
the treatment group in comparison with the placebo group. Summary RR for clinical 
improvement in 6 trials was 14.17 with a 95% CI of 1.19–168.93 (P = 0.036) in 
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efﬁ cacy of VSL#3 (all doses) comparing to placebo and slightly more effective for 
VSL#3 (6 g/day) comparing to placebo with RR of 20.35 with a 95% CI of 6.16–
67.22 (P < 0.0001). Efﬁ cacy of antibiotics comparing to placebo showed a summary 
RR of 2.68 with a 95% CI of 0.4–17.99 and P = 0.3107 for clinical improvement in 
three trials. The summary RR for efﬁ cacy of ciproﬂ oxacin comparing to metronidazole 
was 0.68 with a 95% CI of 0.44–1.06 (P = 0.8913). CONCLUSIONS: In conclusion, 
alongside the beneﬁ t of probiotics and antibiotics in the management of pouchitis, 
effects of probiotics and antibiotics on pouchitis vary according to different mixtures 
of microorganisms strains in probiotics and different spectrums of antibiotics.
PGI4
PREVALENCE AND INCIDENCE OF HEPATITIS A IN A UNITED STATES 
MANAGED CARE CLAIMS DATABASE
Changolkar AK1, Eisenberg D2, Misurski DA1
1GlaxoSmithKline, Philadelphia, PA, USA; 2HealthCore, Wilmington, DE, USA
OBJECTIVES: To evaluate the prevalence and incidence of hepatitis a in a managed 
care population, segmented by a range of characteristics including age, gender, geog-
raphy, and health insurance plan. METHODS: This was an observational retrospec-
tive cohort study utilizing medical and pharmacy claims data for January 1, 2005 
through December 31, 2008 from the Impact National Managed Care Database 
(Benchmark Database). The index date was deﬁ ned as the date of the ﬁ rst and only 
diagnostic claim for hepatitis a within the intake period. All prevalence results reported 
below are per 100,000 and incidence is presented as per person years. RESULTS: Out 
of a total of 94,985,124 subjects in the database, females and males were represented 
equally (51% and 49% respectively). The 45–64 year age group had the greatest 
percentage of subjects. The prevalence of hepatitis a among men and women were 
almost equal (9 and 8, respectively). The 45–54 years age group had the highest hepa-
titis a prevalence (4) followed by the 25–34, 35–44, and 55–64 age groups (3 for each 
group). The largest hepatitis a prevalence rate was from the northeast region (7) fol-
lowed by the south (6). In the 2005–2008 timeframe, hepatitis a prevalence was similar 
in each year (4). Incidence rates across age, region and speciﬁ c zip codes in person 
years were less than 1 person per year. The incidence was slightly higher in males. 
Among three digit zip codes, the zip codes “100” showed higher incidences each year 
with higher prevalence. CONCLUSIONS: In a large commercially insured US popula-
tion, we observed similar prevalence rates of hepatitis a for males and females. The 
disease was most prevalent in the 45–54 years age group. The northeast had the 
highest prevalence rate from 2005–2008. 
GASTROINTESTINAL DISORDERS – Cost Studies
PGI5
A BUDGET IMPACT ANALYSIS OF THE HEPATITIS C TREATMENT 
WITH PEGYLATED INTERFERON IN BRAZIL
Fonseca M, Araújo GTBD
AxiaBio, São Paulo, Brazil
OBJECTIVES: Cost-effectiveness analyses of new hepatitis C drugs have been used to 
select and approve drugs that should be ﬁ nanced by the public health care system. 
However there are still a huge amount of uncertainties within these studies. The fact 
of having pharmacoeconomic and budget impact data of these new pharmacological 
alternatives will help to select the most efﬁ cient alternative. With this, the objective is 
to perform a budget impact analysis (BIA) of the treatment with pegylated interferon 
(pegIFN), alfa-2a or alfa-2b, plus ribavirin in, economically active genotype I patients, 
aging from 30 to 59 years, with chronic hepatitis C (CHC). METHODS: An interac-
tive model has been designed from the inputs obtained from the medical literature. 
Both strategies have been considered as therapeutic equivalents, without signiﬁ cative 
difference in side effects, and as having the same price. RESULTS: The number of 
patients with CHC evaluated in the model has been of 355,611, 15.2% between 30 
and 39 years, 13% between 40 and 49 years and 9% between 50 and 59 years, 
mimicking the Brazilian population and with an average weight of 70.6 kg. The dura-
tion of treatment was 48 weeks, with virologic response measured in weeks 2.4,12.24 
and 48. a total of 91% and 99.8% of the patients receiving pegIFN alfa-2a or alfa-2b, 
respectively achieved sustained virological response at 72 weeks. Total cost was R$ 
4,012,531,131.29 and R$3,752,238,973.99 for the treatment with pegIFN alfa-2a + 
RIB and pegIFN alfa-2b + RIB, respectively. CONCLUSIONS: Although cost-effec-
tiveness analysis appears to be favorable to pegIFN alfa-2a + RIB, a BIA seems to 
favour pegIFN alfa-2b + RIB due to its better predictability in the 12nd week of treat-
ment. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with 
pegIFN alfa-2a + RIB) is an efﬁ cient strategy.
PGI6
COST-EFFECTIVENESS OF MR ELASTOGRAPHY FOR DIAGNOSING 
LIVER FIBROSIS: PRELIMINARY THRESHOLD ASSESSMENT
Lee DW1, Palathinkara V1, Dekoven M2
1GE Healthcare, Waukesha, WI, USA; 2IMS Health, Falls Church, VA, USA
OBJECTIVES: MR Elastography (MRE) is a non-invasive test under clinical trial 
evaluation for effectiveness in helping diagnose liver ﬁ brosis. This study estimated the 
accuracy needed for MRE to be cost-neutral from a US payer’s perspective. 
METHODS: We constructed a decision-analytic model comparing diagnostic costs 
under two scenarios for patients with suspected liver ﬁ brosis: 1) biopsy, or 2) MRE 
followed by biopsy when the MRE test was positive. We conducted a targeted litera-
ture review and consulted with a leading hepatologist and pathologist to identify the 
appropriate procedure codes associated with liver biopsy; we assumed MRE would 
be reimbursed using CPT-4 code 74,181 (magnetic resonance (eg., proton) imaging, 
abdomen; without contrast material(s)). We assigned the appropriate allowable 
charges to the identiﬁ ed procedure codes using the 2010 Medicare Physician Fee 
Schedule. Finally, we assumed negative predictive values (NPV) of 0.8, 0.9 and 0.95, 
and that patients with a false-negative MRE ultimately received a biopsy. RESULTS: 
The cost of a liver biopsy was $1424 (ultrasound $164, surgical $881, pathology 
$347, laboratory $32) and the cost of an MRE (without contrast) was $946 (hospital 
setting) or $666 (non-hospital setting). In a hospital setting, MRE is potentially cost 
saving if the test-negative rate is greater than 83%, 74% and 70% for NPVs of 0.8, 
0.9 and 0.95, respectively. In a non-hospital setting, MRE can reduce diagnostic costs 
when more than 58%, 52% and 49% or patients have negative MRE results for the 
corresponding NPV values. CONCLUSIONS: The cost of liver biopsy is substantial 
as compared to MRE. MRE offers the potential of reducing the cost of diagnosing 
liver ﬁ brosis by avoiding unnecessary biopsies. Cost saving potential increases with 
MRE’s negative predictive value and negative test rate.
PGI7
ECONOMIC BURDEN OF OPIOID INDUCED CONSTIPATION IN SPAIN
Guijarro P1, Alonso-Babarro A2, Viqueira A1, Fernandez G1
1Pﬁ zer Spain, Alcobendas, Madrid, Spain; 2La Paz Hospital, Madrid, Spain
OBJECTIVES: To analyze the use of health care resources and the associated costs in 
patients with opioid induced constipation (OIC). METHODS: An observational, 
retrospective, multicenter study was carried out in Spanish National Health System 
hospitals. All patients were free of constipation at baseline and received opioids for 
at least 2 months. In order to determine patient resource utilization, a review of the 
patient records and patient-interviews were performed to all patients diagnosed with 
OIC. Patients were evaluated depending on response to oral treatment for OIC. The 
observation period was 2 months. The unit costs were obtained from Spanish data-
bases (c 2009). RESULTS: A total of 744 patients were included. Patients had a mean 
(SD) age of 64.2 (13.4) and 48% were male. During the study period, 46.6% of the 
patients developed OIC. Most of these were treated ﬁ rst with oral laxatives exclusively 
(67.7%), 63.8% responded to the treatment and 36.2% did not. Of the total number 
of patients with OIC, 61.5% required a visit to health care services. Forty-four patients 
required a visit to the Emergency Room (ER) and 26 were hospitalized with a median 
length of stay of 3 days. Overall mean total cost (SD) of constipation management 
was c271.08 (c621.22). Resource utilization in responders to oral laxatives was sta-
tistically signiﬁ cant lower than in non-responders. a higher percentage of non-respond-
ers required health care visits, ER visits, and hospitalizations (P < 0.001). The mean 
cost (SD) for each responder was c115 (c230) compared to c442 (c810) for each 
non-responder (P < 0.001). CONCLUSIONS: OIC increases health care resource 
utilization particularly in patients with a poor response to oral laxatives. The economic 
burden of OIC was 3.8 times higher in non-responders than in responders.
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HIDDEN COSTS OF ROTAVIRUS DISEASE—A RETROSPECTIVE 
MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA
Morgan C1, Adlard NE2, Carroll SM2
1Cardiff Research Consortium Ltd, CARDIFF, UK; 2Sanoﬁ  Pasteur MSD, Maidenhead, UK
OBJECTIVES: To determine the impact of rotavirus (RV) disease as a secondary 
diagnosis on hospital length of stay (LOS) and cost for children under ﬁ ve years of 
age in England. METHODS: The study was based on Hospital Episodes Statistics for 
England 2001–2007 using a matched cohort design. Admissions with a secondary 
diagnosis of RV were extracted and matched by age, year of admission and, where 
relevant, therapeutic procedure, to other admissions from HES with the same primary 
diagnosis. Primary admissions were classiﬁ ed as potentially related or unrelated to 
RV. LOS was compared using the paired Wilcoxon test. RESULTS: Of 2126 admis-
sions with a secondary diagnosis of RV, 707 (33.3%) had no other secondary diag-
noses. Of these, 385 admissions were matched for primary diagnosis to controls. 
Median LOS for admissions was 2.0 days (Inter-Quartile Range [IQR] 1.0–4.0), mean 
(sd) 3.2 (4.1) compared with median 1.0 (IQR 0.0–1.5), mean 1.4 (sd 3.5) for control 
admissions (p-value < 0.001). Median cost/admission was £771 (IQR £604–£1090), 
mean cost was £1105 (sd £1064) compared with median £650 (IQR £564–£1090), 
£902 (sd 1004) (p-value < 0.001). a total of254/385 admissions were deﬁ ned as 
unrelated to RV. For these admissions, median LOS was 2.0 days (IQR 1.0–4.25), 
mean 3.7 (sd 4.5) compared with median 1.0 (IQR 0.0–2.0), mean 1.6 (sd 4.0) for 
control admissions (p-value < 0.001). Median cost/admission was £918 (IQR £564–
£1090), mean £1132, (sd £1132) compared with median £771 (IQR £564–£1090), 
mean £980 (sd £1187), (p-value < 0.001). CONCLUSIONS: As a secondary diagnosis 
in HES, RV has a signiﬁ cant incremental impact on LOS and cost. Variations in testing 
and reporting of RV mean that HES data may signiﬁ cantly under represent the overall 
burden of RV disease. This implies that standard modelling methodologies may 
underestimate the true burden of RV disease in the context of health care acquired 
infection.
